source
- First-Line Danvatirsen Plus Pembrolizumab Fails to Improve Response Rates in Metastatic HNSCCDanvatirsen in combination with pembrolizumab did not result in an ORR improvement vs pembrolizumab alone in first-line recurrent/metastatic HNSCC.onclive · 2mo ago↗ source
- Cumulative ADC Toxicities and Closing Reflections: Managing Edema, Fatigue, and Optimizing Long-Term TolerabilityThis concluding segment addresses cumulative toxicities affecting long-term antibody-drug conjugate tolerability, with Hope Rugo, MD and Aaron Lisberg, MD discussing edema, fatigue, and strategies…onclive · 2mo ago↗ source
- The aging scientific workforce collides with rising fabricating citations in medical journalsThe latest in the hantavirus cruise ship saga, why these former officials left the FDA, and more health news from Morning Rounds